177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study

计划入组 93 人 · 首次发布于 2022 年 8 月 11 日

Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment

计划入组 455 人 · 首次发布于 2020 年 12 月 1 日

HEAT Trial (HER2 Antibody Therapy With Lutetium-177)

计划入组 30 人 · 首次发布于 2025 年 2 月 13 日

[Lu-177]-PNT2002

Lutetium-177 EVG321

Lutetium-177 EBRGD

Laureate Institute for Brain Research

United States

Aveta Biomics, Inc.

United States

Selcuk University

Turkey

SPLASH Trial: Lutetium-177 Demonstrates Efficacy in Advanced Prostate Cancer

SHINE Technologies Secures European Marketing Authorization for Lutetium-177 Radioisotope Ilumira

GlyTherix and Eckert & Ziegler Sign Agreement for Lutetium-177 Supply